Movement Alert｜Kelun-Biotech Rises 3.03% in Regular Trading, Investment Banks Raise Target Prices as Public Funds Trigger Disclosure Threshold

Market Focus07-22

On July 22, Kelun-Biotech rose 3.03% in regular trading, trading at 520.5 HKD/share, with turnover of approximately 145 million HKD.

On the news front, multiple international investment banks recently raised target prices for the company. JPMorgan lifted its target from 535 HKD to 648 HKD, while Goldman Sachs raised its target to 582.95 HKD and maintained a Buy rating, citing optimism for the global commercialization prospects of the core product sac-TMT. Goldman Sachs raised its probability of success for the Lung06 study from 81% to 90% and lifted overseas first-line NSCLC indication success probability from 54% to 63%.

Simultaneously, several top public fund managers including Huatianfu have been aggressively accumulating Hong Kong-listed innovative drug stocks. Kelun-Biotech's public fund shareholding ratio has touched the 5% statutory disclosure threshold following these purchases, reinforcing market confidence through sustained long-term institutional capital inflows. This wave of institutional positioning reflects professional investors' recognition of the innovative drug sector's valuation recovery and long-term value.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1121335533?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-22 09:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1121335533","market":"us","top_or_hot":-1,"title":"Movement Alert｜Kelun-Biotech Rises 3.03% in Regular Trading, Investment Banks Raise Target Prices as Public Funds Trigger Disclosure Threshold","media":"Market Focus","content":"<p><p>On July 22, Kelun-Biotech rose 3.03% in regular trading, trading at 520.5 HKD/share, with turnover of approximately 145 million HKD.</p><p>On the news front, multiple international investment banks recently raised target prices for the company. JPMorgan lifted its target from 535 HKD to 648 HKD, while Goldman Sachs raised its target to 582.95 HKD and maintained a Buy rating, citing optimism for the global commercialization prospects of the core product sac-TMT. Goldman Sachs raised its probability of success for the Lung06 study from 81% to 90% and lifted overseas first-line NSCLC indication success probability from 54% to 63%.</p><p>Simultaneously, several top public fund managers including Huatianfu have been aggressively accumulating Hong Kong-listed innovative drug stocks. Kelun-Biotech's public fund shareholding ratio has touched the 5% statutory disclosure threshold following these purchases, reinforcing market confidence through sustained long-term institutional capital inflows. This wave of institutional positioning reflects professional investors' recognition of the innovative drug sector's valuation recovery and long-term value.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Kelun-Biotech Rises 3.03% in Regular Trading, Investment Banks Raise Target Prices as Public Funds Trigger Disclosure Threshold</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Kelun-Biotech Rises 3.03% in Regular Trading, Investment Banks Raise Target Prices as Public Funds Trigger Disclosure Threshold\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-22 09:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 22, Kelun-Biotech rose 3.03% in regular trading, trading at 520.5 HKD/share, with turnover of approximately 145 million HKD.</p><p>On the news front, multiple international investment banks recently raised target prices for the company. JPMorgan lifted its target from 535 HKD to 648 HKD, while Goldman Sachs raised its target to 582.95 HKD and maintained a Buy rating, citing optimism for the global commercialization prospects of the core product sac-TMT. Goldman Sachs raised its probability of success for the Lung06 study from 81% to 90% and lifted overseas first-line NSCLC indication success probability from 54% to 63%.</p><p>Simultaneously, several top public fund managers including Huatianfu have been aggressively accumulating Hong Kong-listed innovative drug stocks. Kelun-Biotech's public fund shareholding ratio has touched the 5% statutory disclosure threshold following these purchases, reinforcing market confidence through sustained long-term institutional capital inflows. This wave of institutional positioning reflects professional investors' recognition of the innovative drug sector's valuation recovery and long-term value.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06990","symbol_name":"科伦博泰生物","start_time":0,"source_url":"","article_id":"1121335533","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1121335533","pubTimestamp":1784685456,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 22, Kelun-Biotech rose 3.03% in regular trading, trading at 520.5 HKD/share, with turnover of approximately 145 million HKD.On the news front, multiple international investment banks recently...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06990":"科伦博泰生物"},"translate_title":"走势预警|科伦生物常规交易涨3.03%，公募基金触发披露门槛，投行上调目标价","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06990":1},"content_text":"On July 22, Kelun-Biotech rose 3.03% in regular trading, trading at 520.5 HKD/share, with turnover of approximately 145 million HKD.On the news front, multiple international investment banks recently raised target prices for the company. JPMorgan lifted its target from 535 HKD to 648 HKD, while Goldman Sachs raised its target to 582.95 HKD and maintained a Buy rating, citing optimism for the global commercialization prospects of the core product sac-TMT. Goldman Sachs raised its probability of success for the Lung06 study from 81% to 90% and lifted overseas first-line NSCLC indication success probability from 54% to 63%.Simultaneously, several top public fund managers including Huatianfu have been aggressively accumulating Hong Kong-listed innovative drug stocks. Kelun-Biotech's public fund shareholding ratio has touched the 5% statutory disclosure threshold following these purchases, reinforcing market confidence through sustained long-term institutional capital inflows. This wave of institutional positioning reflects professional investors' recognition of the innovative drug sector's valuation recovery and long-term value.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1121335533","isCrawlerRequest":true}